Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.

Hdl Handle:
http://hdl.handle.net/10147/208852
Title:
Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.
Authors:
O'Brien, G C; Cahill, R A; Bouchier-Hayes, D J; Redmond, H P
Affiliation:
Dept of Academic Surgery, Cork University Hospital and NUI.
Citation:
Ir J Med Sci. 2006 Jan-Mar;175(1):10-4.
Journal:
Irish journal of medical science
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208852
PubMed ID:
16615221
Abstract:
BACKGROUND: Recombinant interleukin-2(rIL-2) therapy in metastatic melanoma is limited by toxicities, particularly vascular leak syndrome(VLS). Taurolidine potentiates the anti-neoplastic effects of IL-2 while reducing its associated endothelial cell dysfunction in experimental settings. We hypothesized that co-administration of rIL-2 with taurolidine could enhance tolerability without weakening effectiveness. METHODS: Eleven patients with progressive metastatic melanoma received high-dose rIL-2 with co-infusion of taurolidine. Patients were monitored for the development of toxicities and evidence of response. RESULTS: Ten patients tolerated twenty-nine courses of high-dose rIL-2 without dose-reduction. Most toxicities were low-grade. No patient developed VLS. Seven patients died from disease progression. Two had complete clinical and radiological responses to treatment. Two patients remain alive despite evidence of disease progression a mean of 17.5 months after diagnosing metastatic disease. CONCLUSION: Co-administration of taurolidine with high-dose rIL-2 in stage IV melanoma patients appears to greatly enhance the tolerability of this regime without diminishing its therapeutic value.
Language:
eng
MeSH:
Adult; Drug Combinations; Female; Humans; Immunotherapy; Interleukin-2/*therapeutic use; Ireland; Male; Melanoma/*drug therapy/secondary; Middle Aged; Skin Neoplasms/*drug therapy/*secondary; Taurine/*analogs & derivatives/therapeutic use; Thiadiazines/*therapeutic use
ISSN:
0021-1265 (Print); 0021-1265 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Brien, G Cen_GB
dc.contributor.authorCahill, R Aen_GB
dc.contributor.authorBouchier-Hayes, D Jen_GB
dc.contributor.authorRedmond, H Pen_GB
dc.date.accessioned2012-02-03T15:05:28Z-
dc.date.available2012-02-03T15:05:28Z-
dc.date.issued2012-02-03T15:05:28Z-
dc.identifier.citationIr J Med Sci. 2006 Jan-Mar;175(1):10-4.en_GB
dc.identifier.issn0021-1265 (Print)en_GB
dc.identifier.issn0021-1265 (Linking)en_GB
dc.identifier.pmid16615221en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208852-
dc.description.abstractBACKGROUND: Recombinant interleukin-2(rIL-2) therapy in metastatic melanoma is limited by toxicities, particularly vascular leak syndrome(VLS). Taurolidine potentiates the anti-neoplastic effects of IL-2 while reducing its associated endothelial cell dysfunction in experimental settings. We hypothesized that co-administration of rIL-2 with taurolidine could enhance tolerability without weakening effectiveness. METHODS: Eleven patients with progressive metastatic melanoma received high-dose rIL-2 with co-infusion of taurolidine. Patients were monitored for the development of toxicities and evidence of response. RESULTS: Ten patients tolerated twenty-nine courses of high-dose rIL-2 without dose-reduction. Most toxicities were low-grade. No patient developed VLS. Seven patients died from disease progression. Two had complete clinical and radiological responses to treatment. Two patients remain alive despite evidence of disease progression a mean of 17.5 months after diagnosing metastatic disease. CONCLUSION: Co-administration of taurolidine with high-dose rIL-2 in stage IV melanoma patients appears to greatly enhance the tolerability of this regime without diminishing its therapeutic value.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshDrug Combinationsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunotherapyen_GB
dc.subject.meshInterleukin-2/*therapeutic useen_GB
dc.subject.meshIrelanden_GB
dc.subject.meshMaleen_GB
dc.subject.meshMelanoma/*drug therapy/secondaryen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshSkin Neoplasms/*drug therapy/*secondaryen_GB
dc.subject.meshTaurine/*analogs & derivatives/therapeutic useen_GB
dc.subject.meshThiadiazines/*therapeutic useen_GB
dc.titleCo-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.en_GB
dc.contributor.departmentDept of Academic Surgery, Cork University Hospital and NUI.en_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.